Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Editorials
You have accessRestricted Access

Twenty-First Century Solutions to Increase Medication Optimization and Safety in Kidney Transplant Patients

Wendy L. St. Peter and Timothy D. Aungst
CJASN May 2021, 16 (5) 679-681; DOI: https://doi.org/10.2215/CJN.04160321
Wendy L. St. Peter
1Department of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wendy L. St. Peter
Timothy D. Aungst
2Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Worcester, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • kidney transplantation
  • medication optimization
  • medication safety
  • pharmacists

In 2019, 7% of adult kidney transplant recipients experienced acute rejection within 1 year of transplant; a higher percentage (9%) was experienced by younger recipients (18–34 years old) (1). Optimizing immunosuppressant and other medications by improving adherence and preventing medication errors in the post-transplant period are likely key factors in reducing graft loss and hospitalization (2,3). Assuring that immunosuppressive therapy is safe, is effective, and can be taken by the patient as intended in the context of their other conditions and medications is crucial to reducing immunosuppression adverse events and poor health outcomes. There is a need for innovative, cost-effective solutions to reduce medication therapy problems in patients with kidney transplants to reduce graft loss, reduce hospitalizations, and improve survival.

In this issue of CJASN, Gonzales et al. (4) evaluated the effects of a pharmacist-led digital health intervention in patients with kidney transplants compared with usual care in a 1-year, randomized controlled, parallel-arm, semiblinded study (n=136) on medication errors, adverse events, and hospitalizations. Adult kidney transplant recipients who were between 6 and 36 months post-transplant were eligible. Control and intervention patients received usual care, including pharmacist care during the transplant hospitalization and for 6 months post-transplant. Patients in the intervention group received supplemental clinical pharmacist–led medication therapy monitoring and management between 6 and 36 months post-transplant utilizing a smartphone application (app) compared with the usual care group. The app allowed for two-way communication between the pharmacist and transplant recipient and captured home-based (BP, blood glucose, medication administration, and medication adverse events) and electronic health record (EHR; tacrolimus drug levels, health care appointments, and medication refill data from SureScripts) data (5). Data were compiled in a Health Insurance Portability and Accountability Act-compliant web-based portal to allow pharmacists to identify high-risk patients and determine clinical interventions and frequency of follow-up telepharmacy visits. The app allowed patients to easily call the transplant center and pharmacy; to send email alerts to the pharmacist when a medication changed; and to document new medications, health care visits, and side effects or transmit BP or blood glucose information from Bluetooth home monitoring devices. The patient’s medication list was automatically updated when changes were made in EHR. No patient-level data were stored on the device. Information on several medication safety risk factors (tacrolimus level variability, systolic BP, blood glucose, missed appointments, self-reported medication adherence, and patient symptoms) was collected. The pharmacist was alerted when a safety threshold was surpassed based on their standard operating procedure manual risk factor scoring system. This information guided frequency of telepharmacy visits. The study measured the number and severity of medication errors and adverse events as well as hospitalizations (4).

Gonzales et al. (4) showed that medication errors were reduced by more than half in the intervention versus control group. There were differences between groups in some important baseline characteristics that could have affected results, so they adjusted for some (but not all) of these factors in multivariable models. They demonstrated a significant 61% reduction in the incident risk rate of medication errors over the 12-month period. They also showed that the intervention group had a significant 45% lower incident risk of grades 3–5 adverse events. A grade 3 adverse event is a severe or medically significant adverse event that is not immediately life threatening, but may result in a hospitalization or prolonged hospitalization. A grade 4 adverse event is a life-threatening event where urgent intervention is indicated, and grade 5 is death related to the adverse event. Unadjusted hospitalizations per patient-year were also fewer (1.08 versus 0.65). After adjustment, the intervention showed a significant 54% reduction in hospitalization as compared with control. The primary causes of hospitalization were infection, AKI, and cardiovascular- or gastrointestinal-related conditions, which mirrored the types of adverse events reported.

Gonzales et al. (4) have demonstrated that a multifaceted pharmacist-led intervention including an app interfaced with the patients’ EHR and providing a patient and pharmacist portal for two-way communication significantly reduced medication errors, adverse events, and hospitalizations in adult patients with kidney transplants. This study moves beyond other investigations, which have shown varying results on medication adherence, BP control, and postmyocardial infarction outcomes using apps that only engage patients unilaterally (7,8). This study adds to a growing understanding that improving important patient outcomes, such as medication adherence (9), as well as reducing hospitalizations in patients with transplants requires a multifaceted approach and two-way communication between patients and health providers that promote trusted therapeutic relationships.

This study had several strengths. It was a well-designed study; the study team had generated preliminary data and patient/provider experiences that supported the study design, sample size determination, and design of and functionality of the app. Only two patients (intervention group) discontinued the study, and they were included in the intent-to-treat analysis. Blinded researchers determined medication errors, adverse effects, and severity independent of patient care pharmacists. Importantly, they evaluated process (number of medication errors and adverse events), intermediate outcome (reduction in medication errors and grades 3–5 adverse events), and health outcome (hospitalization) metrics. Linking changes in intermediate outcomes to health outcome metrics is critical.

There were limitations to the generalizability of this single-center study. Of 774 adult transplant recipients assessed for eligibility, 501 were excluded; the most common reason for ineligibility was not meeting the post-transplant study window of 6–36 months (specific numbers are not given) (4). Of 273 eligible patients, 137 declined to participate—a portion of those felt uncomfortable with technology after training, but numbers were not given, calling into question how easy the app was to use. Patients were required to self-report medication adherence through the app; given the number of medications that patients with kidney transplants are prescribed, this could be a time-consuming endeavor. Integration of other digital health technology to track adherence (e.g., smart pill bottles or containers) may increase objectivity in measuring adherence and reduce patient load (9). The authors pointed out that they did not use educational text messaging or other “attention control” tools in control patients and did not capture patient education level. Individual components of the intervention (mobile health app, pharmacist-led care, and increased patient attention) could not be separately evaluated to determine their direct effect on study outcomes.

The small sample size contributed to significant clinical differences in study participants’ baseline characteristics, which may have affected study results. There were several characteristics suggesting that the intervention group recipients or donors were healthier at baseline (4). Compared with controls, fewer intervention subjects had diabetes (28% versus 52%), intervention subjects were more likely to be on peritoneal dialysis than hemodialysis, donor age was younger, Kidney Donor Risk Index was lower, and recipients were less likely to be cytomegalovirus positive at transplant. However, higher percentages of intervention participants were more likely to experience delayed graft function and have donor-positive, recipient-negative cytomegalovirus serostatus. Some but not all of these characteristics were adjusted for in multivariable models. Other exploratory end points that investigators were going to evaluate included acute rejection, infections, graft function, and graft failure, but they were not reported. The study was underpowered for these outcomes, but it would be important to evaluate trends to inform future research.

The authors note that an economic analysis is pending, which will include inpatient, outpatient, device, and data plan costs as well as personnel costs to train patients to use the app and pharmacist time. Demonstration of cost-effective data-driven pharmacist care utilizing digital health services will be instrumental in enhancing value-based care in patients with kidney diseases. The Centers for Medicare and Medicaid Services recently launched a new value-based Kidney Care Choice Model that incentivizes kidney transplantation, including a bonus for each beneficiary who receives a kidney transplant (10). The bonus (maximum of $15,000) is paid out over 3 years if the transplant remains successful. It would also encourage a more standardized approach of pharmacist care post-transplant. Transplant centers have multidisciplinary transplant teams, including pharmacists, but the roles and responsibilities of pharmacists vary between transplant centers for pre- and postkidney transplant care.

Additional data from this study would be helpful for other transplant centers to implement and integrate similar digital technology and pharmacist services in transplant programs. Details on workflow transformation and implementation issues may be of benefit for institutions looking to engage in similar digital health services in transplant care. These details could include time metrics on activities related to intervention or time savings from this new process. Further information on patient use experiences, such as performing and uploading their BP and blood glucose reading and personal medication data, related to the app would be useful. Information on how their organization or pharmacy department created buy-in to engage practitioners and patients in this app platform and new service would also be helpful. Finally, many will be interested to know if this app will be available free of charge or on the open market.

Overall, this was a well-designed and well-conducted study that leveraged a novel digital health technology to engage patients in their own self-care management and integrate pharmacist expertise in addressing medication therapy problems to reduce medication errors, adverse events, and hospitalizations in adult patients 6–36 months postkidney transplantation. We are eagerly awaiting the economic analysis that determines the return on investment for incorporation of these new approaches into value-based care of these patients.

Disclosures

T.D. Aungst reports consultancy agreements with Eli Lilly, Otsuka Pharmaceuticals, and Teva Pharmaceuticals; serving as a scientific advisor or member of The Digital Therapeutics Alliance and HealthXL; and speakers bureau for Otsuka Pharmaceuticals and Teva Pharmaceuticals. W.L. St. Peter reports consultancy agreements with Total Renal Care, Inc.; receiving honoraria from the American Nephrology Nursing Association, Integritas Group, and OptumLabs; serving as a scientific advisory board member for the National Kidney Foundation; and other interests/relationships with Centers for Medicare and Medicaid Services Technical Expert Panel on Development of a Quality Measure Assessing Delay in Progression of Chronic Kidney Disease (CKD), National Kidney Foundation and American Society of Nephrology Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases and Technical Expert Panel for Quality Insights Kidney Care Pilot project.

Funding

None.

Acknowledgments

The content of this article reflects the personal experience and views of the author(s) and should not be considered medical advice or recommendation. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or CJASN. Responsibility for the information and views expressed herein lies entirely with the author(s).

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related article, “Pharmacist-Led Mobile Health Intervention and Transplant Medication Safety: A Randomized Controlled Clinical Trial,” on pages 776–784.

  • Copyright © 2021 by the American Society of Nephrology

References

  1. ↵
    US Department of Health & Human Services; The Scientific Registry of Transplant Recipients: OPTN/SRTR 2019 Annual Data Report: Kidney, 2019. Available at: https://srtr.transplant.hrsa.gov/annual_reports/2019/Kidney.aspx. Accessed March 8, 20211
  2. ↵
    1. Taber DJ,
    2. Spivey JR,
    3. Tsurutis VM,
    4. Pilch NA,
    5. Meadows HB,
    6. Fleming JN,
    7. McGillicuddy JW,
    8. Bratton CF,
    9. Treiber FA,
    10. Baliga PK,
    11. Chavin KD
    : Clinical and economic outcomes associated with medication errors in kidney transplantation. Clin J Am Soc Nephrol 9: 960–966, 2014
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Sellarés J,
    2. de Freitas DG,
    3. Mengel M,
    4. Reeve J,
    5. Einecke G,
    6. Sis B,
    7. Hidalgo LG,
    8. Famulski K,
    9. Matas A,
    10. Halloran PF
    : Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 12: 388–399, 2012
    OpenUrlCrossRefPubMed
  4. ↵
    1. Gonzales H,
    2. Fleming J,
    3. Gebregziabher M,
    4. Posadas A,
    5. Su Z,
    6. McGillicuddy J,
    7. Taber C
    : Pharmacist-led mobile health intervention and transplant medication safety: A randomized controlled clinical trial. Clin J Am Soc Nephrol 16: 776–784, 2021
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Taber DJ,
    2. Pilch NA,
    3. McGillicuddy JW,
    4. Mardis C,
    5. Treiber F,
    6. Fleming JN
    : Using informatics and mobile health to improve medication safety monitoring in kidney transplant recipients. Am J Health Syst Pharm 76: 1143–1149, 2019
    OpenUrlCrossRefPubMed
  6. US Department of Health & Human Services; National Cancer Institute: Common Terminology Criteria for Adverse Events, Version 5.0, 2017. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Accessed March 11, 2021
  7. ↵
    1. Morawski K,
    2. Ghazinouri R,
    3. Krumme A,
    4. Lauffenburger JC,
    5. Lu Z,
    6. Durfee E,
    7. Oley L,
    8. Lee J,
    9. Mohta N,
    10. Haff N,
    11. Juusola JL,
    12. Choudhry NK
    : Association of a smartphone application with medication adherence and blood pressure control: The MedISAFE-BP randomized clinical trial. JAMA Intern Med 178: 802–809, 2018
    OpenUrlCrossRefPubMed
  8. ↵
    1. Volpp KG,
    2. Troxel AB,
    3. Mehta SJ,
    4. Norton L,
    5. Zhu J,
    6. Lim R,
    7. Wang W,
    8. Marcus N,
    9. Terwiesch C,
    10. Caldarella K,
    11. Levin T,
    12. Relish M,
    13. Negin N,
    14. Smith-McLallen A,
    15. Snyder R,
    16. Spettell CM,
    17. Drachman B,
    18. Kolansky D,
    19. Asch DA
    : Effect of electronic reminders, financial incentives, and social support on outcomes after myocardial infarction: The HeartStrong randomized clinical trial. JAMA Intern Med 177: 1093–1101, 2017
    OpenUrl
  9. ↵
    1. Foster BJ,
    2. Pai ALH,
    3. Zelikovsky N,
    4. Amaral S,
    5. Bell L,
    6. Dharnidharka VR,
    7. Hebert D,
    8. Holly C,
    9. Knauper B,
    10. Matsell D,
    11. Phan V,
    12. Rogers R,
    13. Smith JM,
    14. Zhao H,
    15. Furth SL
    : A randomized trial of a multicomponent intervention to promote medication adherence: The teen adherence in kidney transplant effectiveness of intervention trial (TAKE-IT) [published correction appears in Am J Kidney Dis 73: 578, 2019 10.1053/j.ajkd.2019.01.009]. Am J Kidney Dis 72: 30–41, 2018
    OpenUrlCrossRefPubMed
  10. ↵
    Centers for Medicare & Medicaid Services: Kidney Care Choices (KCC) Model, 2020. Available at: https://innovation.cms.gov/innovation-models/kidney-care-choices-kcc-model. Accessed March 14, 2021
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 16 (5)
Clinical Journal of the American Society of Nephrology
Vol. 16, Issue 5
May 08, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Twenty-First Century Solutions to Increase Medication Optimization and Safety in Kidney Transplant Patients
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Twenty-First Century Solutions to Increase Medication Optimization and Safety in Kidney Transplant Patients
Wendy L. St. Peter, Timothy D. Aungst
CJASN May 2021, 16 (5) 679-681; DOI: 10.2215/CJN.04160321

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Twenty-First Century Solutions to Increase Medication Optimization and Safety in Kidney Transplant Patients
Wendy L. St. Peter, Timothy D. Aungst
CJASN May 2021, 16 (5) 679-681; DOI: 10.2215/CJN.04160321
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Funding
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Transplant Nephrology
  • Telehealth and Kidney Disease Care
  • Time to Abandon Kidney Biopsy to Diagnose Membranous Nephropathy?
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Pharmacist-Led Mobile Health Intervention and Transplant Medication Safety
  • PubMed
  • Google Scholar

Keywords

  • kidney transplantation
  • medication optimization
  • medication safety
  • pharmacists

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire